Harmony Biosciences Presents Preclinical Data for BP1.15205 OX2R Agonist in Narcolepsy

Harmony Biosciences Holdings, Inc.

Data presented at SLEEP 2025 showed significant wake-promoting and cataplexy-suppressing effects in transgenic mouse model of narcolepsy type 1.
BP1.15205 demonstrated high potency (EC50=0.015 nM) and >600-fold selectivity over human OX1R.
No adverse events were observed in 3-month GLP toxicity study at doses up to 300 mg/kg/day.
First-in-human study planned for 2H 2025 with topline data anticipated in 2026.
IMPD application with EMA being completed; IND for BP1.15205 to be filed with FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.